ArticlePloS one2016
Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.British journal of clinical pharmacology · 2021Pooled it
- Randomized trial of intravenous iron-induced hypophosphatemia.JCI insight · 2018Trial
- Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.American journal of hematology · 2018Trial
- Article
- Hypophosphatemia after intravenous ferric carboxymaltose in lung transplant recipients.Internal and emergency medicine · 2026Article
- Article
- Recurrent Severe Hypophosphatemia Following Intravenous Ferric Carboxymaltose Infusion: A Case Report.Cureus · 2026Article
- The Significance of Hypophosphatemia in Deciding on an Optimal Clinical Choice of Parenteral Iron Therapy in Patients with Chronic Inflammatory Bowel Disease in Slovenia: An Umbrella Review and Economic Evaluation.Healthcare (Basel, Switzerland) · 2026Article
- Prevalence, predictors, and natural history of hypophosphatemia following iron infusion.JBMR plus · 2025Article
- A retrospective analysis of the prevalence of hypophosphatemia and hypocalcemia after intravenous iron polymaltose in the inpatient setting.JBMR plus · 2025Article
- "Double trouble": the impact of iron infusion and antiresorptive therapy on calcium-phosphate homeostasis.JBMR plus · 2025Article
- Article
- Distinct roles of ferric carboxymaltose and ferric derisomaltose on phosphate homeostasis in iron deficiency anemia.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2025Article
- Understanding and Managing Infusion Reactions and Hypophosphataemia With Intravenous Iron-A Nurses' Consensus Paper.Nursing open · 2025Article
- No longer to be ignored: Hypophosphatemia following intravenous iron administration.Reviews in endocrine & metabolic disorders · 2025Review
- TRANSIENT HYPOPHOSPHATEMIA AS POSSIBLE ADVERSE OUTCOME AFTER IRON DEFICIENCY ANEMIA TREATMENT WITH FERRIC CARBOXYMALTOSE - SINGLE CENTER EXPERIENCE.Acta clinica Croatica · 2024Article
- High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.Drug safety · 2022Article
- Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.The Journal of clinical endocrinology and metabolism · 2022Article
- Severe Hypophosphatemia Occurring After Repeated Exposure to a Parenteral Iron Formulation.Case reports in endocrinology · 2022Article
- Refractory hypophosphatemia following ferric carboxymaltose administration.CEN case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFerric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allow correction of severe iron deficiency in a single infusion. A transient decrease in serum phosphate concentrations is a frequent side effect of FCM.
aimTo characterize this adverse event and search for its predictors in a gastroenterology clinic patient cohort.
methodsElectronic medical records of patients attending the University Hospital of Innsbruck were searched for the keywords ferric carboxymaltose or iron isomaltoside. Eighty-one patients with documented administration of FCM or IIM with plasma phosphate concentrations before and after treatment were included.
resultsThe prevalence of hypophosphatemia (<0.8 mmol/L) increased from 11% to 32.1% after treatment with i.v. iron. The hypophosphatemia risk was greater after FCM (45.5%) compared with IIM (4%). Severe hypophosphatemia (<0.6 mmol/L) occurred exclusively after FCM (32.7%). The odds for hypophosphatemia after i.v. iron treatment were independently determined by baseline phosphate and the choice of i.v. iron preparation (FCM vs. IIM-OR = 20.8; 95% CI, 2.6-166; p = 0.004). The median time with hypophosphatemia was 41 days, but prolonged hypophosphatemia of ≥ 2 months was documented in 13 of 17 patients in whom follow-up was available. A significant increase in the phosphaturic hormone intact FGF-23 in hypophosphatemic patients shows that this adverse event is caused by FCM-induced hormone dysregulation.
conclusionTreatment with FCM is associated with a high risk of developing severe and prolonged hypophosphatemia and should therefore be monitored. Hypophosphatemia risk appears to be substantially lower with IIM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.